Immix Biopharma Reports Mid-Stage Trial Data for AL Amyloidosis Therapy
Immix Biopharma (IMMX) saw its stock rise following the release of mid-stage trial data for NXC-201, a therapy targeting AL amyloidosis. The positive results contributed to an increase in share price.
Tickers: $IMMX
Topics: biopharma rare disease trial update